Medications for Adenocarcinoma
6 results
Bizengri (zenocutuzumab)
(Zenocutuzumab)Merus US, Inc.
Usage: BIZENGRI is indicated for adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma that possess a neuregulin 1 (NRG1) gene fusion and have progressed after prior systemic therapy. Approval is based on overall response rate and duration of response.
Fluorouracil (fluorouracil)
(Fluorouracil)Meitheal Pharmaceuticals Inc.
Usage: Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of the colon and rectum, breast, stomach, and pancreas.
Fluorouracil (fluorouracil)
(Fluorouracil)BluePoint Laboratories
Usage: The drug is indicated for the treatment of pancreatic adenocarcinoma, primarily as a therapeutic option to manage and alleviate symptoms associated with this type of cancer.
Fluorouracil (fluorouracil)
(FLUOROURACIL)Eugia US LLC
Usage: Fluorouracil injection is indicated for treating patients with adenocarcinoma of the colon and rectum, breast, stomach, and pancreas.
Lynparza (olaparib)
(olaparib)AstraZeneca Pharmaceuticals LP
Usage: Lynparza is indicated for maintaining treatment in various cancers, including advanced ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations or HRD-positive status, often in conjunction with chemotherapy or targeted therapies. Patient selection should utilize an FDA-approved companion diagnostic.
Onivyde (irinotecan hydrochloride)
(IRINOTECAN HYDROCHLORIDE)Ipsen Biopharmaceuticals, Inc.
Usage: ONIVYDE is indicated for adult patients with metastatic pancreatic adenocarcinoma, used in combination with oxaliplatin, fluorouracil, and leucovorin for first-line treatment, and with fluorouracil and leucovorin after progression on gemcitabine-based therapy. Not indicated as a single agent.